RSV Passive Immunization 69% Effective in Protecting Infants
The Eurosurveillance Rapid Communication published a study on January 25, 2024, that concluded Beyfortus™ (Nirsevimab) was about 69% effective at preventing pediatric respiratory syncytial virus (RSV) hospitalizations in infants. This study provides early real-world evidence of nirsevimab immunization protecting infants from severe RSV disease in Luxembourg, with a significant decrease in RSV cases among infants under six months old.
Significant Shift in Healthcare as More Than One-Third of American Adults Embrace Alternative Therapies
Healthcare is undergoing a significant shift as more than one-third of American adults are now incorporating alternative therapies into their medical care. According to a recent study published in JAMA, 37 percent of adult pain patients utilized nontraditional medical care…
Study Links Living in Poor Neighborhoods to Worse Stroke Recovery
Living in poor neighborhoods has been found to be linked to worse stroke recovery, according to a preliminary study to be presented at the American Stroke Association’s International Stroke Conference 2024. The study revealed that stroke survivors living in areas…
Study Reveals Over 70% Conceal Symptoms of Contagious Illnesses
More than 70% of the participants in a recent study reported concealing their symptoms of contagious illnesses, shedding light on a concerning trend in public health. The study, which involved over 4,100 participants, revealed that 75% of individuals had either…
Genomic Medicine Revolutionizing Cancer Care with Whole-Genome Sequencing
Genomic medicine is leading a revolution in cancer care, with whole-genome sequencing at its core. This tool can sequence a person’s DNA in its entirety, providing a comprehensive test for potential genetic factors contributing to cancer development. Cancer has become…
FDA Grants Breakthrough Device Designation to Click Therapeutics’ CT-155 for Schizophrenia Treatment
Click Therapeutics’ prescription digital therapeutic (PDT) CT-155 has been granted Breakthrough Device designation by the FDA for the treatment of negative symptoms of schizophrenia in adults. The smartphone app, developed in collaboration with Boehringer Ingelheim, is currently being investigated in…
Study Examines Impact of Varying COVID-19 Vaccination Rates on Population-Level Health Outcomes in the U.S.
In a recent study published in BMC Public Health, researchers examined the impact of varying COVID-19 vaccination rates on population-level health outcomes across different waves of the virus in the United States. The study focused on the association between time-varying…
Walmart Launches First ‘Wellness Day’ of 2024 with Emphasis on HPV Vaccination
Walmart Launches First ‘Wellness Day’ of 2024 with Emphasis on HPV Vaccination By: Nimrah Khatoon Published: January 18, 2024 at 4:56 pm EST Walmart, the multinational retail corporation, spearheaded the first ‘Wellness Day’ of 2024 in the Hattiesburg area, signaling…
Critical Drug Shortages Leave Cancer Patients in the U.S. Waiting Over a Year for Life-Saving Medication
Patients with cancer in the United States are facing a critical issue as they are forced to wait over a year for life-saving medication, which costs just $10, due to record-high drug shortages. The average wait time for a drug…
BrightSpring Health Services Aims for $3.01 Billion Valuation in US IPO
KKR-backed BrightSpring Health Services has set a target valuation of around $3.01 billion for its long-awaited initial public offering in the United States. The company, specializing in providing care to patients with complex or chronic medical conditions, is moving forward…